I way I look at this company is that its currently valued significantlybelow its replacement cost (very low Q-ratio) and therefore future downside islimited from this point (bear case). My base case is for a steady continuationof improvements in current businesses with share prices returning to cap raiselevels and bull case sees a huge spike once bio-dynamic organic infant formulais announced. Launching into a new niche segment of the IF market with LBsteering the ship will see the hype of 2017 return.
Intrinsic Value, page-15
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
